
NGM Biopharmaceuticals Investor Relations Material
Latest events

Study Result
NGM Biopharmaceuticals

Q4 2023
11 Mar, 2024

Corporate Presentation
9 Jan, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from NGM Biopharmaceuticals Inc
Access all reports
NGM Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of liver and metabolic diseases, retinal diseases, and cancer. The company's key products in development include NGM707, a dual antagonist monoclonal antibody for advanced metastatic solid tumors, and Aldafermin, an engineered analog of a human hormone aimed at treating liver diseases such as non-alcoholic steatohepatitis. Additionally, NGM Biopharmaceuticals works on a variety of other drug candidates targeted at different therapeutic areas, using a biologics-based platform to create and evaluate monoclonal antibodies and other proteins. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
NGM
Country
🇺🇸 United States